期刊文献+

Safety of Dabigatran in Patients with Non-valvular Atrial Fibrillation: A Short-Term Registry

Safety of Dabigatran in Patients with Non-valvular Atrial Fibrillation: A Short-Term Registry
下载PDF
导出
摘要 Dabigatran is a new oral anticoagulant that has been approved by the Food and Drug Administration for the treatment of patients with NVAF (non-valvular atrial fibrillation). The paper is to retrospectively evaluate the safety of dabigatran in patients with NVAF. We performed a retrospective cohort analysis of our registries for patients using dabigatran. The clinical safety endpoints included major bleeding, stroke, death, and any other reported or documented adverse events. All other major and minor events were recorded and documented during the treatment period. Of the 80 patients included in the analysis, 26% of those receiving a dose of 150 mg experienced adverse events, including two cases of minor bleeding and one case of stroke, whereas 8% of those receiving a dose of 110 mg experienced adverse events, including one case of major gastric bleeding and one case of death. The most common adverse event was gastric distress. Moreover, we noted cases of minor urethral and optic nerve bleeding, major gastric bleeding, stroke, and death. Treatment with dabigatran is primarily successful in low-risk profile patients, without any major or minor events, whereas high-risk patients may require further evaluation before dabigatran treatment initiation and careful monitoring during the treatment period.
出处 《Journal of Pharmacy and Pharmacology》 2014年第9期565-569,共5页 药剂与药理学(英文版)
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部